Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female 18 y/o and older~2. Female patients must be practicing an effective method of birth control~3. Biopsy-proven AL-amyloidosis~4. Must have been previously treated (failed at least 1 previous treatment) and in the opinion of the physician, patient requires further treatment~Exclusion Criteria:~1. Hypersensitivity to boron or mannitol~2. Prior treatment with VELCADE~3. Patient requires other concomitant chemotherapy, radiotherapy or ancillary therapy considered investigational~4. Uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): VELCADE

Based on this trial design, predict the completion outcome and termination type (if applicable).